Abstract: Assay methods for diagnosing blood clotting disorders are described. The assays use data bases for pooled normal plasma (PNP) and plasma from healthy volunteers, males and females ages 18 to 64 years. Charting on a comparative basis of patient plasma and PNP allows the results to be interpreted by reference to the data base. Simple, rapid, inexpensive and highly sensitive and specific assays devised for diagnosing blood clotting disorders are described.

Abstract: The present invention is directed to a method for arresting or inhibiting the growth of cells in Kaposi's Sarcoma lesions and a method for arresting or inhibiting the growth of the Kaposi's Sarcoma lesions, said methods comprising contacting the cells in the lesions with an effective amount of SP-PG, a naturally occurring sulfated polysaccharide-peptidoglycan produced by a specific species of the bacterium Arthrobacter, AT-25. The invention is also directed to blocking or inhibiting the activity of cellular vascular permeability factor(s), which comprises contacting vascular cells with an effective amount of SP-PG. In one embodiment, there is provided a method for blocking or inhibiting increased vascular permeability (and resulting edema) in diseases and disorders in which the increased vascular permeability contributes to the pathology, for example, in Kaposi's Sarcoma, tumorigenesis, inflammation, diabetic retinopathy, etc.

Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.

Abstract: The present invention relates to several types of antimicrobial peptides including reverse antimicrobial peptides, antimicrobial oligopeptides and other antimicrobial compositions, such as cecropin P1. The present invention also relates to the use of these antimicrobial peptides to provide organisms, and, in particular, plants, with protection from microbial pathogens. Finally, the present invention relates to a screening method which may be useful for determining the phytotoxity of an antimicrobial peptide.

Abstract: This invention relates to novel peptides based on a thrombin receptor sequence and novel methods for synthesis of these novel peptides. These peptides, branched-chain compounds and/or derivatized solid supports containing TRPs may be used diagnostically or therapeutically.

Abstract: The invention relates to synthetic proteins that can be used in in vitro sensing devices to detect the presence of physiologically active substances. The synthetic proteins are mimetic to native ion channels in mammalian systems. The invention also relates to a biosensor comprising a support assembly, a synthetic lipid bilayer containing the active channel protein. Lastly, the invention relates to the use of the biosensor disclosed in the application for the in vitro detection of physiologically active substances including antiseptics, antibiotics, neurotransmittors, and others.

Abstract: Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.

Abstract: A process for the solid phase synthesis of peptides containing an aza-amino acid, for example the decapeptide goserelin, which comprises:(i) assembling all the amino acids of the peptide except the C-terminal aza-amino acid by conventional solid phase synthesis;(ii) cleaving the peptide from the support with hydrazine or a substituted hydrazine; and(iii) reacting the hydrazide thus released with a cyanate ion.

Abstract: Methods for treatment of diabetes and other insulin-requiring conditions by administering insulin and a calcitonin with or without amylin, and methods for treatment of hypoglycemic conditions by administering a calcitonin alone or in combination with glucagon and/or an amylin, and related compositions.

Abstract: A method for decreasing the concentration of free actin in the plasma of an animal is described which comprises the administration of native and modified actin-binding proteins, and especially the administration of native and modified actin-binding regions of gelsolin. Diagnostic methods for identifying animals in need of such treatment are also described.

Abstract: The present invention pertains to an alpha, beta-heterodimeric polypeptide having binding affinity to vertebrate luteinizing hormone (LH) receptors and vertebrate follicle stimulating hormone (FSH) receptors comprising a glycoprotein hormone alpha-subunit polypeptide and a non-naturally occurring beta-subunit polypeptide, wherein the beta-subunit polypeptide is a chain of amino acids comprising the following four joined subsequences:(a) a first subsequence homologous to the amino acid sequence of residues 1-93 of the beta-subunit selected from the group consisting of human chorionic gonadotrophin (hCG), vertebrate luteinizing hormone (LH), vertebrate follicle stimulating hormone (FSH), and vertebrate thyroid stimulating hormone (TSH);(b) a second subsequence homo logous to the amino acid sequence of residues 94-97 of the beta-subunit selected from the group consisting of human chorionic gonadotrophin (hCG) and vertebrate luteinizing hormone (LH);(c) a third subsequence homologous to the amino acid sequence of

Abstract: A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.

Abstract: New insulin derivatives, a process for their preparation and use, and a pharmaceutical formulation containing them are disclosed. The derivatives contain the basic amino acid arginine at the amino-terminal position of the insulin A-chain, and various amino acid substitutions at the carboxyl terminus of the insulin B-chain. The compounds are suitable for the treatment of diabetes mellitus, have a delayed profile of action and are very well tolerated.

Abstract: Herein disclosed are several pentapeptide methyl ester derivatives of dolatin 10, using both naturally occurring and modified amino acids. The selected modified amino acids are constituents of dolastatin 10 which is a structurally distinct peptide with excellent in vitro and in vivo antineoplastic activity.

Abstract: Human urine trypsin inhibitor is provided as an agent for treating acquired immunodeficiency syndrome (AIDS), preventing the infection with AIDS or preventing the onset of AIDS after such infection. It can be administered intravenously for the treatment and externally for the prevention.

Abstract: Antitumor peptides of the formula ##STR1## where R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings stated in the description, and the preparation thereof.

Abstract: Decapaptide and undecapaptides substituted on the N-terminal nitrogen atom by acyl groups which include furo-2-yl, isonicotinyl, nicotinyl, 2-, 3-, and 4-quinolinecarbonyl, shikimyl, dihydroshikimyl, and tetrahydrofur-2-oyl are potent antagonists of LHRH and are useful for suppressing the levels of sex hormones in mammals.

Abstract: Novel peptides of the formula ##STR1## in which R.sup.1, R.sup.2, X, A, R.sup.3, B, D, E, R.sup.7, M, Q, a, b and d have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.

Abstract: Diuresis, natriuresis, and the lowering of blood pressure are produced in a host by administering one or more neutral endopeptidase inhibitors. An additional blood pressure lowering agent such as an angiotensin converting enzyme inhibitor can be administered along with the neutral endopeptidase inhibitor.

Abstract: The cytostatic cycloheptapeptide stylostatin 2 was isolated respectively, from the South and Western Pacific Ocean sponges Stylotella sp. and Phakellia costata. Structural determination was accomplished by utilizing high-field (500 MHz) 2D-NMR experiments and confirmed by an X-ray crystal structure determination to provide the assignment cyclo(Pro-Leu-Ile-Phe-Ser-Pro-Ile). The absolute configuration was established by chiral gas chromatographic analytical technique. The cyclic heptapeptide backbone was found to include a .beta.-turn, type VIa, incorporating a cis peptide bond, at -Ser-Pro.